Your browser doesn't support javascript.
loading
Impavido attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice.
Traughber, C Alicia; Iacano, Amanda J; Neupane, Kalash; Khan, Mariam R; Opoku, Emmanuel; Nunn, Tina; Prince, Ashutosh; Sangwan, Naseer; Hazen, Stanley L; Smith, Jonathan D; Gulshan, Kailash.
Afiliación
  • Traughber CA; Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115, USA.
  • Iacano AJ; Department of Biology, Geology, and Environmental Sciences, Cleveland State University, Cleveland, OH 44115, USA.
  • Neupane K; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Khan MR; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Opoku E; Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115, USA.
  • Nunn T; Department of Biology, Geology, and Environmental Sciences, Cleveland State University, Cleveland, OH 44115, USA.
  • Prince A; Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115, USA.
  • Sangwan N; Department of Biology, Geology, and Environmental Sciences, Cleveland State University, Cleveland, OH 44115, USA.
  • Hazen SL; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Smith JD; Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Gulshan K; Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115, USA.
iScience ; 26(4): 106453, 2023 Apr 21.
Article en En | MEDLINE | ID: mdl-37020959
Impavido (Miltefosine) is an FDA-approved drug for treating leishmaniasis and primary amebic meningoencephalitis. We have shown previously that Miltefosine increased cholesterol release and dampened Nlrp3 inflammasome assembly in macrophages. Here, we show that Miltefosine reduced LPS-induced choline uptake by macrophages, and attenuated Nlrp3 inflammasome assembly in mice. Miltefosine-fed mice showed reduced plasma IL-1ß in a polymicrobial cecal slurry model of systemic inflammation. Miltefosine-fed mice showed increased reverse cholesterol transport to the plasma, liver, and feces. Hyperlipidemic apoE-/- mice fed with WTD + Miltefosine showed significantly reduced weight gain and markedly reduced atherosclerotic lesions versus mice fed with WTD. The 16S rDNA sequencing and analysis of gut microbiota showed marked alterations in the microbiota profile of Miltefosine-fed hyperlipidemic apoE-/- versus control, with the most notable changes in Romboutsia and Bacteriodes species. Taken together, these data indicate that Miltefosine causes pleiotropic effects on lipid metabolism, inflammasome activity, atherosclerosis, and the gut microbiota.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos